.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Julphar
Cantor Fitzgerald
UBS
Boehringer Ingelheim
Dow
Colorcon
Merck
Fish and Richardson
Farmers Insurance

Generated: July 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,179,569

« Back to Dashboard

Details for Patent: 4,179,569

Title: N-(4-piperidinyl)-N-phenylamides
Abstract:Novel N-(4-piperidinyl)-N-phenylamides and -carbamates having very potent analgesic activity, methods of preparing same and useful intermediates therefor.
Inventor(s): Janssen; Paul A. J. (Vosselaar, BE), Van Daele; Georges H. P. (Turnhout, BE)
Assignee: Janssen Pharmaceutica N.V. (Beerse, BE)
Filing Date:Dec 19, 1977
Application Number:05/862,073
Claims:1. A compound selected from the group consisting of a piperidine derivative having the formula: ##STR102## and the stereochemical optical isomeric forms thereof, wherein: Z is a member selected from the group consisting of hydrogen, halo, lower alkyl, lower alkyloxy and trifluoromethyl;

X is a member selected from the group consisting of hydrogen and methyl;

L.sup.2 is a member selected from the group consisting of alkyl having from 3 to 10 carbons and lower alkenyl; and

R.sup.13 is a carboxylate radical represented by the formula: ##STR103## wherein R.sup.2 is a member selected from the group consisting of lower alkyl, lower alkenyl and phenylmethyl.

2. Ethyl 1-(1-methylethyl)-4-(phenylamino)-4-piperidinecarboxylate.

3. Methyl 1-(1-methylethyl)-4-phenylamino)-4-piperidinecarboxylate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Healthtrust
McKesson
Julphar
Chubb
Federal Trade Commission
Cipla
Harvard Business School
Cerilliant
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot